Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories has entered into a strategic collaboration with Amgen - one of the world’s leading independent biotechnology companies - to market and distribute three Amgen medicines in India in the areas of oncology and cardiology.

Under the terms of the collaboration, the company shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and RepathaTM (evolocumab) in India. The collaboration leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with Dr. Reddy's deep understanding of patient and physician needs in India.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.